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Conclusions: This study shows that the radiochromic silicone 
based 3D dosimeter is dose-rate independent with 0.25 % 
(w/w) LMG and 1 % (w/w) chloroform. This greatly enhances 
its usability in clinical environments, however, the decreased 
stability of the dosimeter due to the increased LMG 
concentration must be carefully considered. 
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Purpose/Objective: The new DMI MV imaging panel with 
Eclipse/Aria permits measurements of FFF integrated images 
and configuration of the Portal Dosimetry algorithm ('PDIP') 
for QA of IMRT and Rapid Arc ('RA') treatment plans. This 
study evaluates the commissioning procedure for the Portal 
Dosimetry ('PD') system for FFF energies and the resulting 
implementation for IMRT and RA pre-treatment QA. To 
evaluate the accuracy and performance of the PD system, 
measurements were also performed using the new Octavius 
1500 system.  
Materials and Methods: A Varian TrueBeam equipped with 
HD-MLC and the new DMI imager was used to configure and 
evaluate the PDIP algorithm. The DMI panel has high 
resolution imaging capabilities and together with the new 
version of Eclipse/Aria (V.13) allows for configuration of the 
PDIP for use with FFF energies. The PDIP was configured for 
use at 100 cm SDD by measuring the imager output factors 
and an ideal fluence provided by Varian. The 6 MV was used 
as the standard for performance evaluation of the imager and 
PD configuration for the 6 and 10 FFF energies. Measured 
output factors, open fields, and test complex fluences were 
compared to those predicted by the PDIP to validate the 
configuration. Test IMRT and RA plans were measured and 
analyzed using the PD software. A further evaluation of the 
PD was performed by repeating fluence and test plan 
measurements on the new Octavius 1500 array system. The 
array was commissioned with solid water plates and also 
inserted in the cylindrical rotational polystyrene phantom 
(Octavius 4D). The latter setup was used with an inclinometer 
to assess the agreement between measured and planned 
doses and for comparison with results obtained on the PD. 
Volumetric (3D) and planar (2D) gamma analysis are available 
for the reconstructed dose volume to check the dose in a 
volume or in a plane, respectively. All fluences and test plans 
were analyzed using the gamma criteria of 2%-2mm and 10% 
dose threshold. 
Results: The PDIP algorithm showed agreement within <1% 
between the measured and calculated output factors for 6 
MV and 6 FFF and within <1.5% for 10 FFF. The open field and 
test fluences on the PD system resulted in a gamma passing 
criteria >99.0% and >97.2%, respectively. The test IMRT plans 
resulted in gamma analysis >99.2% (<γ>=99.7±0.4%) on the 
PD, >96.5% (<γ>=98.0±1.6%) on the Octavius with 2D analysis, 
and >97.1% (<γ>=97.5±0.5%) on the Octavius with 3D analysis. 
The test RA plans resulted in a gamma analysis >97.0% 
(<γ>=99.0±1.2%) on the PD and >97.8% (<γ>=99.0±0.7%) on 
the Octavius with 3D analysis (Figure: 10FFF RA;Table: RA 
analysis).  
 
 
Conclusions: The Portal Dosimetry system for the TrueBeam 
with DMI imager can be used for IMRT and RA pretreatment 
QA verification for FFF energies. The results obtained with 
the PD were comparable to those obtained with direct 
measurement equipment such as the PTW Octavius 1500. The 
PD system has higher resolution and measurement points 
which could have resulted in a slightly higher gamma analysis 
passing rate when compared to the Octavius. 
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Purpose/Objective: This work evaluates the potential of the 
new aS1200 EPID (Varian Medical Systems) for pre-treatment 
and in vivo dosimetry (IVD) applications. 
Materials and Methods: Measurements were performed using 
one aS1200 and an older aS1000 unit, both mounted on 
matched TrueBeam linacs. Comparative specifications are in 
Table 1. 
